This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Allen, M. I.
Right arrow Articles by Condreay, L. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Allen, M. I.
Right arrow Articles by Condreay, L. D.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, October 1999, p. 3338-3347, Vol. 37, No. 10
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Two Sensitive PCR-Based Methods for Detection of Hepatitis B Virus Variants Associated with Reduced Susceptibility to Lamivudine

Marchelle I. Allen,1,* Josee Gauthier,1 Manon DesLauriers,2 Eric J. Bourne,1 Kevin M. Carrick,3 Fausto Baldanti,4 Lisa L. Ross,1 Michael W. Lutz,5 and Lynn D. Condreay1

Departments of Virology,1 Functional Genetics,3 and Research Information Resources,5 Glaxo Wellcome, Inc., Research Triangle Park, North Carolina 27709-3398; Centers for Disease Control, National Center for Infectious Diseases/Division of AIDS, Sexually Transmitted Diseases, and Tuberculosis Laboratory, Atlanta, Georgia 303332; and Laboratori Sperimentali di Ricerca, IRCCS Policlinico S. Matteo, 27100 Pavia, Italy4

Received 26 March 1999/Returned for modification 24 May 1999/Accepted 19 July 1999

Two novel assays, a restriction fragment length polymorphism (RFLP) assay and an assay based on the 5'-nuclease activity of Taq DNA polymerase, were developed for screening viral variants in lamivudine-treated patients' sera containing <1,000 copies of the hepatitis B virus (HBV) genome per ml. Both assays were designed to detect single-nucleotide changes within the HBV DNA polymerase gene that are associated with lamivudine resistance in vitro and have been used to screen a number of patients' sera for variant virus. Results obtained with these assays and standard sequencing technology were compared with regard to throughput, ability to detect individual virus species present at low concentrations, and ability to detect, distinguish, and quantitate wild-type (wt) and HBV tyrosine methionine552 aspartate aspartate motif variants in mixed viral populations. Unlike DNA sequencing, both assays are amenable to high-throughput screening and were shown to be able to quantitatively detect variant virus in the presence of a background of wt virus. As with DNA sequencing, both new assays incorporate a PCR amplification step and are able to detect the relatively low amounts of virus found in lamivudine-treated patients' sera. However, these assays are far less labor intensive than the DNA-sequencing techniques presently in use. Overall, the RFLP assay was more sensitive than DNA sequencing in detecting and determining the ratios of wt to variant virus. Furthermore, the RFLP assay and 5'-nuclease assay were equally sensitive in the detection of mixed viral species, but the RFLP assay was superior to the 5'-nuclease assay in the quantitation of mixed viral species. These assays should prove useful for further understanding of virological response to therapy and disease progression.

* Corresponding author. Mailing address: Department of Virology, RC2, Rm. 712, Glaxo Wellcome, Inc., P.O. Box 13398, Research Triangle Park, NC 27709-3398. Phone: (919) 483-8413. Fax: (919) 483-9205. E-mail: mia46935{at}glaxowellcome.com.

Journal of Clinical Microbiology, October 1999, p. 3338-3347, Vol. 37, No. 10
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Ntziora, F., Paraskevis, D., Haida, C., Magiorkinis, E., Manesis, E., Papatheodoridis, G., Manolakopoulos, S., Beloukas, A., Chryssoy, S., Magiorkinis, G., Sypsa, V., Hatzakis, A. (2009). Quantitative Detection of the M204V Hepatitis B Virus Minor Variants by Amplification Refractory Mutation System Real-Time PCR Combined with Molecular Beacon Technology. J. Clin. Microbiol. 47: 2544-2550 [Abstract] [Full Text]  
  • Ou, Z.-Y., Liu, N., Chen, C.-J., Cheng, G., He, Y.-S. (2005). Rapid and Accurate Genotyping of YMDD Motif Variants in the Hepatitis B Virus Genome by an Improved Reverse Dot Blot Method. J. Clin. Microbiol. 43: 5685-5689 [Abstract] [Full Text]  
  • Mizukoshi, E., Sidney, J., Livingston, B., Ghany, M., Hoofnagle, J. H., Sette, A., Rehermann, B. (2004). Cellular Immune Responses to the Hepatitis B Virus Polymerase. J. Immunol. 173: 5863-5871 [Abstract] [Full Text]  
  • Jang, H., Cho, M., Heo, J., Kim, H., Jun, H., Shin, W., Cho, B., Park, H., Kim, C. (2004). Oligonucleotide Chip for Detection of Lamivudine-Resistant Hepatitis B Virus. J. Clin. Microbiol. 42: 4181-4188 [Abstract] [Full Text]  
  • Kessler, H. H., Stelzl, E., Marth, E., Stauber, R. E. (2003). Detection of Mutations in the Hepatitis B Virus Polymerase Gene. Clin. Chem. 49: 989-992 [Full Text]  
  • NIESTERS, H. G. M., DE MAN, R. A., PAS, S. D., FRIES, E., OSTERHAUS, A. D. M. E. (2002). Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy. J Med Microbiol 51: 695-699 [Abstract] [Full Text]  
  • Jonas, M. M., Kelley, D. A., Mizerski, J., Badia, I. B., Areias, J. A., Schwarz, K. B., Little, N. R., Greensmith, M. J., Gardner, S. D., Bell, M. S., Sokal, E. M., the International Pediatric Lamivudine Investigato, (2002). Clinical Trial of Lamivudine in Children with Chronic Hepatitis B. NEJM 346: 1706-1713 [Abstract] [Full Text]  
  • Aberle, S. W., Kletzmayr, J., Watschinger, B., Schmied, B., Vetter, N., Puchhammer-Stöckl, E. (2001). Comparison of Sequence Analysis and the INNO-LiPA HBV DR Line Probe Assay for Detection of Lamivudine-Resistant Hepatitis B Virus Strains in Patients under Various Clinical Conditions. J. Clin. Microbiol. 39: 1972-1974 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»